<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03196466</url>
  </required_header>
  <id_info>
    <org_study_id>NI17009HLJ</org_study_id>
    <nct_id>NCT03196466</nct_id>
  </id_info>
  <brief_title>Population Pharmacokinetics of Antiepileptic in Pediatrics</brief_title>
  <acronym>EPIPOP</acronym>
  <official_title>Population Pharmacokinetics of Antiepileptic in Pediatrics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop population pharmacokinetic models for antiepileptic&#xD;
      drugs in a pediatric population.&#xD;
&#xD;
      The interest of these models is multiple:&#xD;
&#xD;
        -  describe the pharmacokinetics of these molecules in children and explain the&#xD;
           inter-individual variability of concentrations through covariates such as weight, age,&#xD;
           co-treatments, genetic polymorphisms and renal function;&#xD;
&#xD;
        -  estimate maximum, minimum and exposure concentrations from the individual&#xD;
           pharmacokinetic parameters for each patient;&#xD;
&#xD;
        -  propose adaptations of doses for certain classes of children (according to age, weight&#xD;
           etc.) and individualize the doses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epilepsy affects about 1% of the population, with a peak incidence in childhood, and&#xD;
      persistent seizures on antiepileptic therapy in approximately 30% of patients. Over the past&#xD;
      two decades, many antiepileptic molecules have emerged, raising the question of their optimal&#xD;
      use, especially in pediatrics, where pharmacokinetics and pharmacodynamics are different from&#xD;
      adults and largely influenced by age and development.&#xD;
&#xD;
      The pharmacokinetics of antiepileptics have been little studied in pediatric populations. In&#xD;
      children, it is important to know if a maturational effect (of age) has to be taken into&#xD;
      account in addition to the physiological effect (of the weight) to adapt the doses. Moreover,&#xD;
      these molecules are often used in combination and lot of enzyme interactions make their use&#xD;
      delicate. All of these factors explain the existence of significant inter-individual&#xD;
      variability in the pediatric population.&#xD;
&#xD;
      The implication of the demographic and medicinal factors mentioned above, as well as the&#xD;
      balance of efficacy / undesirable effects, justify the interest of a pharmacological&#xD;
      monitoring of these drugs in a pediatric population. The use of population pharmacokinetics&#xD;
      is particularly interesting in children because it requires only a small number of samples&#xD;
      per patient and can be used to describe the predominant inter-individual variability in this&#xD;
      population.&#xD;
&#xD;
      The main goal is to develop population pharmacokinetic models for the following antiepileptic&#xD;
      drugs in children: valproic acid, carbamazepine, phenobarbital, phenytoin, levetiracetam,&#xD;
      lamotrigine, topiramate, oxcarbazepine, stiripentol, clobazam, brivaracétam, felbamate,&#xD;
      lacosamide, rufinamide, gabapentine, pregabaline, sultiame, tiagabine, vigabatrine,&#xD;
      mesuximide, primidone, perampanel, ethosuximide, zonisamide and cannabidiol. The interest of&#xD;
      these models is multiple:&#xD;
&#xD;
        -  describe the pharmacokinetics of these molecules in children and explain the&#xD;
           interindividual variability of concentrations through covariates such as weight, age,&#xD;
           co-treatments, genetic polymorphisms and renal function;&#xD;
&#xD;
        -  estimate maximum, minimum and exposure concentrations from the individual&#xD;
           pharmacokinetic parameters for each patient;&#xD;
&#xD;
        -  propose adaptations of doses for certain classes of children (according to age, weight&#xD;
           etc.) and individualize the doses.&#xD;
&#xD;
      The secondary objectives of this work are:&#xD;
&#xD;
        -  Build models jointly with several antiepileptic drugs, accounting for the strength of&#xD;
           interactions between them during multiple therapies.&#xD;
&#xD;
        -  Link antiepileptic concentrations to the effects of treatment (reduction or cessation of&#xD;
           seizures): pharmacokinetic-pharmacodynamic study with concentration / efficacy and&#xD;
           concentration / toxicity relationships.&#xD;
&#xD;
        -  The evaluation of preexisting models in the literature and the comparison of the data&#xD;
           with the results of these models (external validation).&#xD;
&#xD;
      Pharmaco-statistical analysis will be carried out on the retrospective data of patients&#xD;
      treated with one or more antiepileptic molecule (s) and whose blood dosage of the drug(s) as&#xD;
      part of their therapeutic follow-up is available. The study of genetic polymorphisms will be&#xD;
      carried out from available blood samples, collected and stored as part of therapeutic&#xD;
      follow-up of patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2017</start_date>
  <completion_date type="Anticipated">June 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 19, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Volume of distribution</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absorption constant</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite measure of the inter-individual variability</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>Covariates of inter-individual variability : age, weight, co-treatments, genetic polymorphisms and renal function</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <description>Titration of valproic acid, carbamazepine, phenobarbital, phenytoin, levetiracetam, lamotrigine, topiramate, oxcarbazepine, stiripentol, clobazam, brivaracétam, felbamate, lacosamide, rufinamide, gabapentine, pregabaline, sultiame, tiagabine, vigabatrine, mesuximide, primidone, perampanel, ethosuximide, zonisamide and cannabidiol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
    <description>Titration of valproic acid, carbamazepine, phenobarbital, phenytoin, levetiracetam, lamotrigine, topiramate, oxcarbazepine, stiripentol, clobazam, brivaracétam, felbamate, lacosamide, rufinamide, gabapentine, pregabaline, sultiame, tiagabine, vigabatrine, mesuximide, primidone, perampanel, ethosuximide, zonisamide and cannabidiol</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Valproic acid</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>carbamazepine</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>phenobarbital</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>phenytoin</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>levetiracetam</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>lamotrigine</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>topiramate</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>oxcarbazepine</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>stiripentol</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>clobazam</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>brivaracétam</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>felbamate</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>lacosamide</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rufinamide</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gabapentine</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pregabaline</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sultiame</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tiagabine</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>vigabatrine</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mesuximide</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>primidone</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>perampanel</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ethosuximide</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>zonisamide</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cannabidiol</intervention_name>
    <description>titration</description>
    <arm_group_label>antiepileptics titration</arm_group_label>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>genetic polymorphisms</intervention_name>
    <description>genetic polymorphisms</description>
    <arm_group_label>antiepileptics titration and available blood samples</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Minor patient treated by one or more antiepileptics and for which a blood test has been&#xD;
        performed&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children from 0 to 18 years of age with epilepsy;&#xD;
&#xD;
          -  Treatment with one or more antiepileptic drug (s) studied (valproic acid,&#xD;
             carbamazepine, phenobarbital, phenytoin, levetiracetam, lamotrigine, topiramate,&#xD;
             oxcarbazepine, stiripentol, clobazam, brivaracétam, felbamate, lacosamide, rufinamide,&#xD;
             gabapentine, pregabaline, sultiame, tiagabine, vigabatrine, mesuximide, primidone,&#xD;
             perampanel, ethosuximide, zonisamide and cannabidiol);&#xD;
&#xD;
          -  Blood dosage of the drug (s) as part of their therapeutic follow-up in the&#xD;
             Pharmacology laboratory of the Cochin hospital between 2007 and 2019&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient with missing data on time of last drug taking, time of collection,&#xD;
             co-treatments and / or dose administered;&#xD;
&#xD;
          -  patient with doubt about compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc TRELUYER, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Marc TRELUYER, MD, PhD</last_name>
    <phone>01 58 41 28 84</phone>
    <email>jean-marc.treluyer@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hélène Morel</last_name>
    <phone>+33 1 71 19 63 46</phone>
    <email>helene.morel@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AP-HP Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc Treluyer, M.D., PhD</last_name>
      <phone>+ 00 1 58 41 28 85</phone>
      <email>jean-marc.treluyer@parisdescartes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antiepileptics</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>children</keyword>
  <keyword>genetic polymorphisms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Zonisamide</mesh_term>
    <mesh_term>Lacosamide</mesh_term>
    <mesh_term>Carbamazepine</mesh_term>
    <mesh_term>Phenytoin</mesh_term>
    <mesh_term>Oxcarbazepine</mesh_term>
    <mesh_term>Rufinamide</mesh_term>
    <mesh_term>Levetiracetam</mesh_term>
    <mesh_term>Cannabidiol</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Brivaracetam</mesh_term>
    <mesh_term>Phenobarbital</mesh_term>
    <mesh_term>Clobazam</mesh_term>
    <mesh_term>Ethosuximide</mesh_term>
    <mesh_term>Tiagabine</mesh_term>
    <mesh_term>Stiripentol</mesh_term>
    <mesh_term>Primidone</mesh_term>
    <mesh_term>Felbamate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

